Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma

Abstract Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of relapsed or refractory multiple myeloma (RRMM), yet outcomes remain heterogenous. The prognostic role of body composition in this context is unknown. We retrospectively analyzed 108 RRMM patients treated with an...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Thomas C. Wiemers, Michael Rade, Nora Grieb, Maximilian Ferle, Tihomir Dermendzhiev, David Fandrei, Patrick Born, Luise Fischer, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Ronny Baber, Markus Kreuz, Klaus H. Metzeler, Marco Herling, Carmen D. Herling, Madlen Jentzsch, Georg‐Nikolaus Franke, Andreas Boldt, Thomas Neumuth, Urvi A. Shah, Ulrike Köhl, Kristin Reiche, Timm Denecke, Uwe Platzbecker, Vladan Vučinić, Hans‐Jonas Meyer, Maximilian Merz
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2026-03-01
Sarja:	HemaSphere
Linkit:	https://doi.org/10.1002/hem3.70314
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!